INMB Inmune Bio, Inc.
P/E
--
Forward P/E
--
Price/Sales
760.34
Beta
0.898
Div Yield
--
Market Cap
--
Company Analysis
Latest News
INmune Bio Announces $4.5 Million Registered Direct Offering and Private Placement
INmune Bio Inc. entered into a securities purchase agreement with a single institutional investor to raise approximately $4.5 million in gross proceeds through...
INmune Bio Inc Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
Analysts expect INmune Bio to report Q3 2026 revenue of $0.00 million and a loss of $0.15 per share, with the current stock price of $1.46 significantly...
INmune Bio Advances Ebstrocel™ with UK Regulatory Filing and Global Commercial Agreement
INmune Bio announced significant regulatory and commercial progress for its cell therapy, Ebstrocel™, for the treatment of Recessive Dystrophic Epidermolysis...